Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) recorded Other Accumulated Expenses of $37,930 in Q2 2026, down 49.0% from $74,316 a year earlier and down 65.3% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
At the end of FY2025, Inhibikase Therapeutics reported Other Accumulated Expenses of $212,927, up 162.9% from FY2024.
- Annual Other Accumulated Expenses has a five-year compound annual growth rate of 34.1% (FY2020 to FY2025).
- Across earlier years, Other Accumulated Expenses came in at $81,000 in FY2024 (-21.2%), $102,817 in FY2023 (+936.5%), $9,920 in FY2022 (+93.5%) and $5,127 in FY2021 (-89.6%).
- The Q2 2026 figure is the lowest quarterly Other Accumulated Expenses since Q3 2024.
- On a year-over-year basis, Other Accumulated Expenses rose in four of the last eight quarters, with growth averaging 218.6%.
- Peak year-over-year performance for Other Accumulated Expenses in the last five years was growth of 936.5% in Q4 2023, against a decline of 99.6% in Q2 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $109,350 (Q1 2026), $212,927 (Q4 2025) and $116,166 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Inhibikase Therapeutics | 349.14 Mn | -236.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37,930.00 |
| Mar 31, 2026 | 109,350.00 |
| Dec 31, 2025 | 212,927.00 |
| Sep 30, 2025 | 116,166.00 |
| Jun 30, 2025 | 74,316.00 |
| Mar 31, 2025 | 127,703.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 13,050.00 |
| Jun 30, 2024 | 10,931.00 |
| Mar 31, 2024 | 25,561.00 |
| Dec 31, 2023 | 102,817.00 |
| Sep 30, 2023 | 2.74 Mn |
| Jun 30, 2023 | 2.73 Mn |
| Mar 31, 2023 | 2.66 Mn |
| Dec 31, 2022 | 9,920.00 |
| Sep 30, 2022 | 3.07 Mn |
| Jun 30, 2022 | 10,630.00 |
| Mar 31, 2022 | 17,737.00 |
| Dec 31, 2021 | 5,127.00 |
| Sep 30, 2021 | 11,518.00 |
API Access
Inhibikase Therapeutics Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();